Premium
Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study
Author(s) -
Brosseron Frederic,
Kolbe CarlChristian,
Santarelli Francesco,
Carvalho Stephanie,
Antonell Anna,
CastroGomez Sergio,
Tacik Pawel,
Namasivayam Aishwarya Alex,
Mangone Graziella,
Schneider Reinhard,
Latz Eicke,
Wüllner Ullrich,
Svenningsson Per,
SánchezValle Raquel,
Molinuevo José Luis,
Corvol JeanChristophe,
Heneka Michael T.
Publication year - 2020
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.07.018
Subject(s) - neurodegeneration , biomarker , disease , medicine , immunology , neuroinflammation , cerebrospinal fluid , alzheimer's disease , immunity , immune system , oncology , biology , biochemistry
Multiple immunity biomarkers have been suggested as tracers of neuroinflammation in neurodegeneration. This study aimed to verify findings in cerebrospinal fluid (CSF) samples of Alzheimer's disease (AD) and Parkinson's disease (PD) subjects from the network of the European, Innovative Medicines Initiative–funded project AETIONOMY. Methods A total of 227 samples from the studies/centres AETIONOMY, ICEBERG, and IDIBAPS were used to analyse 21 selected immunity biomarkers in CSF. Results were compared to data of an independent cohort of 399 subjects previously published. Results Immunity markers were predominantly and reproducibly associated with pathological levels of tau isoforms, but also with amyloid levels, aging, sex, APOE genotype, and center‐specific factors. Discussion Immunity biomarker levels in CSF reflect molecular and cellular pathology rather than diagnosis in neurodegenerative disorders. Assay standardization and stratification for age and other covariates could improve the power of such markers in clinical applications or intervention studies targeting immune responses in neurodegeneration.